Navigation path

Community Register of medicinal products

Register of not active Orphan Medicinal Products (alphabetical)

Product EU Designation Designated Orphan Indication Sponsor Designation date Tradename
EU Centralised Nr
implemented by
Human monoclonal antibody against HLA-DR EU/3/05/291 Treatment of Hodgkin’s lymphoma GPC Biotech AG 16/06/2005
(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione EU/3/09/678 Treatment of soft tissue sarcoma Gregory Fryer Associates Ltd 8/10/2009
(1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)-bicyclo[2.2.1]hept-5-ene-2-carboxamide benzoate EU/3/10/729 Treatment of acute myeloid leukaemia Merck KGaA 23/03/2010
(R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate EU/3/04/218 Treatment of renal cell carcinoma Innate Pharma SAS 29/07/2004
(Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3Hindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate EU/3/05/268 Treatment of renal cell carcinoma Pfizer Ltd 10/03/2005
(Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3Hindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate EU/3/05/267 Treatment of malignant gastrointestinal stromal tumours Pfizer Ltd 10/03/2005 Sutent
EU/1/06/347/...
11/01/2007
17-(allylamino)-17-demethoxygeldanamycin hydroquinone hydrochloride EU/3/07/512 Treatment of malignant gastro intestinal stromal tumours Voisin Consulting S.A.R.L. 29/11/2007
17-allylamino-17-demethoxygeldanamycin EU/3/04/256 Treatment of chronic myeloid leukemia Bristol-Myers Squibb International Corporation 26/01/2005
17-allylamino-17-demethoxygeldanamycin EU/3/04/247 Treatment of multiple myeloma Bristol-Myers Squibb International Corporation 21/12/2004
2-(4-(diethylamino) phenyl)-6-methyl-2H-benzo[d][1,2,3] triazol-5-amine EU/3/06/385 Treatment of Duchenne muscular dystrophy Vastox plc. 25/07/2006
2’-O-methyl-phosphorothioate oligonucleotide EU/3/06/357 Treatment of Duchenne muscular dystrophy Prosensa B.V. 16/02/2006
26 base single stranded phosphodiester DNA oligonucleotide EU/3/06/353 Treatment of renal cell carcinoma Antisoma Research Ltd 16/02/2006
26 base single stranded phosphodiester DNA oligonucleotide EU/3/06/352 Treatment of pancreatic cancer Antisoma Research Ltd 16/02/2006
26 base single stranded phosphodiester DNA oligonucleotide EU/3/09/662 Treatment of acute myeloid leukaemia Antisoma Research Ltd 8/10/2009
4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid EU/3/03/180 Treatment of chronic iron overload requiring chelation therapy Genzyme Europe B.V. 12/12/2003
4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid EU/3/07/497 Treatment of hepatocellular carcinoma Quintiles Ireland Ltd 22/10/2007
5,10-methylene-tetrahydrofolic acid EU/3/04/221 Treatment of pancreatic cancer in combination with 5-fluorouracil Interface International Consultancy Limited 2/09/2004
5-10-Methylene-tetrahydrofolate EU/3/03/143 Treatment of pancreatic cancer in combination with 5-fluorouracil Interface International Consultancy Limited 11/06/2003
8-cyclopentlyl-1,3-dipropylxanthine EU/3/01/030 Treatment of cystic fibrosis SciClone Pharmaceuticals Italy S.r.l 29/03/2001
a -1-acid glycoprotein EU/3/03/138 Treatment of tricyclic antidepressants poisoning Bio Products Laboratory 20/03/2003
a-1-acid glycoprotein EU/3/03/164 Treatment of cocaine poisoning Bio Products Laboratory 2/10/2003
Abetimus sodium EU/3/01/064 Treatment of lupus nephritis La Jolla Limited 20/11/2001
Acetylcysteine EU/3/04/259 Treatment of idiopathic pulmonary fibrosis Zambon Group Spa 26/01/2005
5-methyl-pyridine-2-sulfonic acid {6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt EU/3/03/150 Treatment of cutaneous T-cell lymphoma Transgene S.A. 9/07/2003
Aldesleukin (inhalation use) EU/3/03/146 Treatment of renal cell carcinoma Chiron Corporation Ltd 30/06/2003
Alfimeprase EU/3/05/322 Treatment of acute peripheral arterial occlusion Quadramed Limited 28/10/2005
Allogeneic human umbilical cord tissue-derived cells EU/3/08/534 Treatment of retinitis pigmentosa Centocor, B.V. 1/04/2008
Alpha-Galactosidase A EU/3/00/002 Treatment of Fabry disease Shire Human Genetic Therapies AB 8/08/2000 Replagal
EU/1/01/189/...
3/08/2001
Alpha-Galactosidase A EU/3/00/003 Treatment of Fabry disease Genzyme Europe B.V. 8/08/2000 Fabrazyme
EU/1/01/188/...
3/08/2001
Ambrisentan EU/3/10/790 Treatment of idiopathic pulmonary fibrosis Gilead Sciences International Ltd 1/10/2010
Amiloride hydrochloride dihydrate EU/3/03/147 Treatment of cystic fibrosis Pulmo Tec GmbH 30/06/2003
Amonafide L-malate EU/3/07/483 Treatment of acute myeloid leukaemia Antisoma Research Limited 22/10/2007
anti-CD147 murine monoclonal IgM EU/3/02/123 Treatment of Graft versus Host Disease SangStat UK Limited 14/11/2002
Anti-EphA2 monoclonal antibody conjugated to maleimidocaproyl monomethylauristatin phenylalanine EU/3/09/682 Treatment of ovarian cancer MedImmune Ltd 28/10/2009
Anti-von Willebrand Aptamer EU/3/08/547 Treatment of thrombotic thrombocytopenic purpura FGK Representative Service GmbH 3/06/2008
Aplidine EU/3/03/151 Treatment of acute lymphoblastic leukaemia Pharma Mar SA Sociedad Unipersonal 9/07/2003
Apomorphine (oromucosal use) EU/3/01/072 Treatment of off-periods in Parkinson´s disease not responding to other oral treatment Orion Corporation 5/12/2001
Arsenic trioxide EU/3/00/008 Treatment of acute promyelocytic leukaemia Cephalon Europe 18/10/2000 Trisenox
EU/1/02/204/...
5/03/2002
Arsenic trioxide EU/3/00/017 Treatment of acute promyelocytic leukaemia Agence générale des équipements et produits de santé - Etablissement pharmaceutique des hôpitaux de Paris (AGEPS-EPHP) 17/01/2001
Arsenic trioxide EU/3/01/031 Treatment of myelodysplastic syndromes Cephalon Europe 29/03/2001
Arsenic trioxide EU/3/07/460 Treatment of acute myeloid leukaemia Cephalon Europe 2/08/2007
Arsenic trioxide EU/3/01/032 Treatment of multiple myeloma Cephalon Europe 29/03/2001
Autologous CD34+ cells transfected with retroviral vector containing the human gp91(phox) gene EU/3/06/393 Treatment of chronic granulomatous disease Vision 7 GmbH 28/08/2006
Autologous urothelial and smooth muscle cells EU/3/08/574 Treatment of spinal cord injury European Medical Advisory Services Limited 7/11/2008
Autologous urothelial and smooth muscle cells EU/3/08/537 Treatment of spina bifida European Medical Advisory Services Limited 17/03/2008
Beraprost sodium EU/3/01/053 Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Aventis Pharma S.A. 18/09/2001
Boswellia serrata resin extract EU/3/02/117 Treatment of peritumoral oedema derived from brain tumours Pharmasan GmbH 21/10/2002
Bryostatin-1 EU/3/02/099 Treatment of oesophageal cancer GPC Biotech AG 30/04/2002
Carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester EU/3/02/105 Treatment of cystic fibrosis Boehringer Ingelheim International GmbH 26/06/2002
Carmustine (solution for intratumoral injection) EU/3/02/085 Treatment of glioma Icon Clinical Research UK Ltd 5/03/2002
Chimeric-anti-interleukin-6 monoclonal antibody EU/3/03/148 Treatment of renal cell carcinoma Janssen Biologics B.V. 30/06/2003
Ciclosporin EU/3/04/196 Treatment of atopic keratoconjunctivitis Allergan Pharmaceuticals Ireland 14/04/2004
Ciclosporin (implant) EU/3/06/415 Prevention of rejection of corneal transplant Lux Biosciences GmbH 3/11/2006
Colistimethate sodium EU/3/02/088 Treatment of Pseudomonas aeruginosa lung infection (including colonisation) in cystic fibrosis Forest Laboratories UK Ltd 19/02/2002
Deuterium oxide EU/3/04/239 Treatment of pancreatic cancer BDD Berolina Drug Development GmbH 20/10/2004
Dexamethasone (intravitreal implant) EU/3/10/763 Treatment of non-infectious uveitis affecting the posterior segment of the eye Allergan Pharmaceuticals Ireland 4/08/2010
Dihydroartemisinin, piperaquine EU/3/07/468 Treatment of malaria Sigma Tau Industrie Farmaceutiche Riunite S.p.A 3/08/2007
Doxorubicin carbon / iron magnetically targeted microparticles EU/3/02/112 Treatment of hepatocellular carcinoma Interface International Consultancy Limited 11/09/2002
Eflornithine hydrochloride EU/3/02/087 Treatment of Familial Adenomatous Polyposis (FAP) ILEX Services Limited 19/02/2002
Eltrombopag olamine EU/3/07/467 Treatment of idiopathic thrombocytopenic purpura GlaxoSmithKline Trading Services Limited 3/08/2007 Revolade
EU/1/10/612/...
11/03/2010
Engineered protein inhibitor of human neutrophil elastase EU/3/03/152 Treatment of cystic fibrosis Debioclinic SA 9/07/2003
Epothilone B EU/3/02/098 Treatment of ovarian cancer Novartis Europharm Ltd 22/03/2002
Eptacog alfa (activated) EU/3/07/436 Treatment of post-neonatal intracerebral haemorrhage Novo Nordisk A/S 20/03/2007
everolimus EU/3/07/488 Treatment of gastro-entero-pancreatic neuroendocrine tumours Novartis Europharm Ltd 14/11/2007
everolimus EU/3/07/449 Treatment of renal cell carcinoma Novartis Europharm Ltd 5/06/2007 Afinitor
EU/1/09/538/...
3/08/2009
Fenretinide EU/3/06/426 Treatment of primary malignant bone tumours Cancer Research UK 26/01/2007
Fenretinide EU/3/06/427 Treatment of soft tissue sarcoma Cancer Research UK 30/01/2007
Fluorouracil EU/3/00/004 Treatment of glioblastoma Ethypharm S.A. 18/10/2000
Fomepizole EU/3/01/040 Treatment of methanol poisoning IDIS Ltd 30/05/2001
GM-CSF receptor antagonist EU/3/02/089 Treatment of juvenile myelomonocytic leukaemia British Biotech Pharmaceuticals Ltd 18/03/2002
H-Tyrosine-Glycine-Phenylalanine-Glycine-Glycine-OH EU/3/03/167 Treatment of chronic idiopathic myelofibrosis Abiogen Pharma S.p.A. 20/10/2003
Human C1-inhibitor EU/3/09/668 Treatment of angioedema caused by C1-inhibitor deficiency ViroPharma SPRL 8/10/2009
Human engineered monoclonal antibody specific for Transforming Growth Factor ß1 EU/3/01/080 Treatment of systemic sclerosis Genzyme Europe B.V. 4/02/2002
Human engineered monoclonal antibody specific for Transforming Growth Factor ß2 EU/3/01/042 Prevention of scarring in glaucoma filtration surgical procedures Cambridge Antibody Technology 30/05/2001
Human Milk Fat Globule 1 / Human Milk Fat Globule 1 - S-p-isothiocyanatobenzyl-diethylenetriaminepentaacetic acid for use with 90Yttrium EU/3/01/043 Treatment of ovarian cancer Antisoma Plc 30/05/2001
Human monoclonal antibody against HLA-DR EU/3/06/358 Treatment of multiple myeloma GPC Biotech AG 28/02/2006
Human monoclonal antibody against HLA-DR EU/3/05/347 Treatment of chronic lymphocytic leukaemia GPC Biotech AG 24/01/2006
Human monoclonal hepatitis B immunoglobulins EU/3/04/187 Prevention of hepatitis B re-infection following liver transplantation ICON Clinical Research (UK) Ltd 23/02/2004
Human Staphylococcus aureus polyclonal immunoglobulin and human Staphylococcus epidermidis polyclonal immunoglobulin EU/3/05/335 Prevention of late onset sepsis in premature infants of less or equal than 32 weeks gestational age Omnicare Clinical Research 14/12/2005
Human transferrin conjugated to mutant diphtheria toxin EU/3/02/090 Treatment of gliomas Xenova Biomedix Limited 19/03/2002
Humanised Anti-HM1.24 Monoclonal Antibody EU/3/01/037 Treatment of multiple myeloma Chugai Pharma Europe Ltd 10/05/2001
Humanized anti-KSA monoclonal antibody - human interleukin-2 fusion protein EU/3/02/097 Treatment of renal cell carcinoma Merck KGaA 22/03/2002
H-Val-Ile-Val-Lys-Leu-Ile-Pro-Ser-Thr-Ser-Ser-Ala-Val-Asp-Thr-Pro-Tyr-Leu-Asp-Ile-Thr-Tyr-His-Phe-Val-Ala-Gln-Arg-Leu-Pro-Leu-OH EU/3/06/398 Treatment of myasthenia gravis Debioclinic SA 28/08/2006
Ibuprofen EU/3/01/027 Prevention of patent ductus arteriosus in premature neonates of less than 34 weeks of gestational age Orphan Europe S.a.r.l. 5/03/2001
Imatinib mesilate EU/3/05/304 Treatment of acute lymphoblastic leukaemia Novartis Europharm Ltd 26/08/2005 Glivec
EU/1/01/198/...
13/09/2006
Imatinib mesilate EU/3/05/305 Treatment of dermatofibrosarcoma protuberans Novartis Europharm Ltd 26/08/2005 Glivec
EU/1/01/198/...
13/09/2006
Imatinib EU/3/01/061 Treatment of malignant gastrointestinal stromal tumours Novartis Europharm Limited 20/11/2001 Glivec
EU/1/01/198/...
24/05/2002
Imatinib mesilate EU/3/05/340 Treatment of myelodysplastic / myeloproliferative diseases Novartis Europharm Ltd 23/12/2005 Glivec
EU/1/01/198/...
28/11/2006
Imatinib mesilate EU/3/05/306 Treatment of mastocytosis Novartis Europharm Ltd 26/08/2005
Imatinib mesilate EU/3/05/320 Treatment of chronic eosinophilic leukaemia and the hypereosinophilic syndrome Novartis Europharm Ltd 28/10/2005 Glivec
EU/1/01/198/...
28/11/2006
Imatinib mesylate EU/3/01/021 Treatment of chronic myeloid leukaemia Novartis Europharm Ltd 14/02/2001 Glivec
EU/1/01/198/...
7/11/2001
Interferon gamma EU/3/05/281 Treatment of idiopathic pulmonary fibrosis InterMune Europe Ltd 27/05/2005
Iodine (131I) anti-CEA sheep-human chimeric monoclonal antibody monoclonal antibody labeled with iodine-131 EU/3/03/142 Treatment of pancreatic cancer Xenova Biomedix Limited 7/05/2003
Lintuzumab EU/3/09/627 Treatment of acute myeloid leukaemia Seattle Genetics UK Limited 30/04/2009
Lintuzumab EU/3/09/626 Treatment of myelodysplastic syndromes Seattle Genetics UK Limited 29/04/2009
Lumiliximab EU/3/08/528 Treatment of chronic lymphocytic leukaemia Biogen Idec Limited 4/02/2008
Lusupultide EU/3/00/016 Treatment of acute respiratory distress syndrome Nycomed GmbH 17/01/2001
Lusupultide EU/3/07/457 Treatment of aspiration pneumonitis requiring intubation and mechanical ventilation Nycomed GmbH 10/07/2007
Mecasermin rinfabate EU/3/06/378 Treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects Insmed Europe Ltd. 20/06/2006
Mecasermin rinfabate EU/3/06/377 Treatment of patients with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH Insmed Europe Ltd. 20/06/2006
Mitotane EU/3/02/113 Treatment of adrenal cortical carcinoma Agence générale des équipements et produits de santé - Etablissement pharmaceutique des hôpitaux de Paris (AGEPS-EPHP) 11/09/2002
Monoclonal antibody to human interleukin-6 EU/3/02/125 Treatment of post-transplant lymphoproliferative disorders EUSA Pharma SAS 18/12/2002
Murine monoclonal antibody to GD2 EU/3/09/644 Treatment of neuroblastoma United Therapeutics Europe Ltd 12/06/2009
Myristoylated-peptidyl-recombinant Human CD59 EU/3/02/114 Treatment of paroxysmal nocturnal haemoglubinuria Orexo AB 11/09/2002
Myristoylated-peptidyl-recombinant SCR1-3 of human complement receptor type I EU/3/02/108 Prevention of post transplantation graft dysfunction Orexo AB 30/07/2002
N-acetylsarcosyl-glycyl-L-valyl-D-allo-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N-ethylamide EU/3/03/181 Treatment of soft tissue sarcoma Abbott International European Office 12/12/2003
Nolatrexed EU/3/03/165 Treatment of hepatocellular carcinoma Scirex Ltd. 2/10/2003
Octovalent Pseudomonas aeruginosa O-polysaccharie-toxin A conjugate vaccine EU/3/01/076 Prevention of Pseudomonas aeruginosa infections in patients with cystic fibrosis Orphan Europe S.a.r.l. 11/12/2001
Opebacan EU/3/06/402 Treatment of meningococcal disease XOMA Ireland Ltd 28/08/2006
Pagibaximab EU/3/10/743 Prevention of sepsis caused by Gram positive pathogens in premature infants less than or equal to 34 weeks of gestational age Theorem Clinical Research GmbH 9/06/2010
Panobinostat EU/3/09/721 Treatment of Hodgkin's lymphoma Novartis Europharm Ltd 2/02/2010
Panobinostat lactate EU/3/07/464 Treatment of cutaneous T-cell lymphoma Novartis Europharm Ltd 2/08/2007
Paromomycin sulphate EU/3/05/271 Treatment of visceral leishmaniasis Sestria Ltd 11/04/2005
Patupilone EU/3/09/688 Treatment of fallopian tube cancer Novartis Europharm Ltd 5/11/2009
Patupilone EU/3/09/687 Treatment of primary peritoneal cancer Novartis Europharm Ltd 5/11/2009
Pazopanib hydrochloride EU/3/06/382 Treatment of renal cell carcinoma Glaxo Group Limited 29/06/2006
Pemetrexed disodium EU/3/01/060 Treatment of malignant mesothelioma Eli Lilly Nederland BV 17/09/2001
Pixantrone dimaleate EU/3/09/722 Treatment of diffuse large B-cell lymphoma CTI Life Sciences Ltd 2/02/2010
Plitidepsin EU/3/10/838 Treatment of post-essential thrombocythaemia myelofibrosis Pharma Mar S.A. Sociedad Unipersonal 23/02/2011
Plitidepsin EU/3/10/837 Treatment of primary myelofibrosis Pharma Mar S.A. Sociedad Unipersonal 23/02/2011
Plitidepsin EU/3/10/839 Treatment of post-polycythaemia vera myelofibrosis Pharma Mar S.A. Sociedad Unipersonal 23/02/2011
Porcine lung surfactant EU/3/01/057 Treatment of acute lung injury Leo Pharmaceutical Products 19/09/2001
Purified inactivated Japanese encephalitis SA14-4-2 virus vaccine EU/3/05/348 Prevention of Japanese encephalitis Intercell AG 24/01/2006 Ixiaro
EU/1/08/501/...
31/03/2009
Ranpirnase EU/3/01/033 Treatment of malignant mesothelioma MoRa Pharma GmbH 29/03/2001
Recombinant adeno-associated viral vector containing human acid alpha-glucosidase-gene EU/3/07/454 Treatment of glycogen storage disease type II (Pompe's disease) TMC Pharma Services Ltd. 9/07/2007
Recombinant human alpha-1 antitrypsin EU/3/02/100 Treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency Aptiv Solutions (UK) Ltd 30/04/2002
Recombinant human alpha-1-antitrypsin (respiratory use) EU/3/01/041 Treatment of emphysema secondary to congenital alpha 1-antitrypsin deficiency Bayer HealthCare AG 30/05/2001
Recombinant human arylsulfatase A EU/3/03/158 Treatment of metachromatic leukodystrophy Shire Pharmaceuticals Ireland Limited 9/07/2003
Recombinant human C1-inhibitor EU/3/01/036 Treatment of angioedema caused by C1 inhibitor deficiency Pharming Group N.V. 11/05/2001
Recombinant human insulin-like growth factor-I / recombinant human insulin-like growth factor binding protein-3 EU/3/04/237 Treatment of Rabson-Mendenhall syndrome Dr Geoffrey Allan 21/10/2004
Recombinant human insulin-like growth factor-I / recombinant human insulin-like growth factor binding protein-3 EU/3/04/238 Treatment of Leprechaunism Insmed Europe Ltd 21/10/2004
Recombinant human insulin-like growth factor-I / recombinant human insulin-like growth factor binding protein-3 EU/3/04/236 Treatment of Type A extreme insulin resistance syndrome Dr Geoffrey Allan 21/10/2004
Recombinant human insulin-like growth factor-I / recombinant human insulin-like growth factor binding protein-3 EU/3/04/235 Treatment of Type B extreme insulin resistance syndrome Insmed Europe Ltd 20/10/2004
Recombinant human insulin-like growth factor-I / recombinant human insulin-like growth factor binding protein-3 EU/3/03/159 Treatment of primary growth hormone insensitivity syndrome (Laron Syndrome) Insmed Europe Ltd 9/07/2003
Recombinant human monoclonal antibody to hsp90 EU/3/01/073 Treatment of invasive fungal infections Novartis Europharm Ltd 5/12/2001
Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class EU/3/08/527 Treatment of systemic-onset juvenile idiopathic arthritis Novartis Europharm Ltd 4/02/2008
Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class EU/3/07/439 Treatment of cryopirin-associated periodic syndromes (Familial Cold Urticaria Syndrome (FCUS), Muckle-Wells Syndrome (MWS), and Neonatal Onset Multisystem Inflammatory Disease (NOMID), also known as Chronic Infantile Neurological Cutaneous Novartis Europharm Ltd 20/03/2007 Ilaris
EU/1/09/564/...
23/10/2009
Recombinant human residue 41 glutamic acid to glutamine variant of Interferon-alfa-2b EU/3/08/606 Treatment of Behçet's disease Creabilis Therapeutics S.p.A. 19/01/2009
Ribavirin EU/3/01/024 Treatment of haemorrhagic fever with renal syndrome ICN Pharmaceuticals Limited 14/02/2001
Ribavirin EU/3/01/029 Treatment of adenovirus infection in immunocompromised patients Valeant Pharmaceuticals Limited 8/03/2001
Sabarubicin EU/3/04/255 Treatment of small cell lung cancer Menarini Ricerche S.p.A. 21/12/2004
Sapropterin EU/3/05/308 Treatment of hyperphenylalaninemia Dr Gunter Schaub 26/08/2005
Seocalcitol EU/3/01/052 Treatment of hepatocellular carcinoma Leo Pharmaceutical Products 31/07/2001
Sinapultide, dipalmitoylfosfatidylcholine, palmitoyloleoyl fosfatidylglycerol and palmitic acid EU/3/01/054 Treatment of Meconium Aspiration Syndrome Discovery Laboratories, Inc 19/09/2001
Sodium dichloroacetate EU/3/04/225 Treatment of systemic monochloroacetate poisoning Dr Anthony W. Fox 2/09/2004
Sodium oxybate EU/3/02/131 Treatment of narcolepsy UCB Pharma Ltd. 3/02/2003 Xyrem
EU/1/05/312/...
13/10/2005
Sodium valproate EU/3/05/309 Treatement of 5q muscular atrophy The Jennifer Trust for Spinal Muscular Atrophy 26/08/2005
Streptococcus pyogenes Su strain cells treated with benzylpenicillin EU/3/09/714 Treatment of congenital lymphatic malformations Theradex (Europe) Ltd. 29/01/2010
Sulfonated monophosphorylated mannose oligosaccharide EU/3/07/482 Treatment of hepatocellular carcinoma Constella Group Ltd 14/09/2007
Tacrolimus hydrate EU/3/03/185 Treatment of vernal keratoconjunctivitis Sucampo Pharma Europa Ltd 14/01/2004
Talampanel EU/3/09/631 Treatment of glioma Teva Pharma GmbH 29/04/2009
Talampanel EU/3/09/646 Treatment of amyotrophic lateral sclerosis Teva Pharma GmbH 12/06/2009
Tegafur / gimeracil / oteracil EU/3/07/515 Treatment of gastric cancer Taiho Pharma Europe Limited 20/12/2007
Thalidomide EU/3/01/066 Treatment of erythema nodosum leprosum (ENL) or type II lepra reactions Celgene Europe Limited 20/11/2001
Thalidomide EU/3/01/068 Treatment of multiple myeloma Kendle International Ltd 19/12/2001
Thalidomide EU/3/01/046 Treatment of Graft versus Host Disease Pharmion France 9/07/2001
Thalidomide EU/3/01/047 Treatment of multiple myeloma Pharmion France 9/07/2001
Thalidomide EU/3/00/009 Treatment of erythema nodosum leprosum (ENL) or type II lepra reactions Pharmion France 29/12/2000
Tilarginine acetate EU/3/05/330 Treatment of cardiogenic shock Dr Ulrich Granzer 18/10/2005
Troxacitabine EU/3/05/311 Treatment of acute myeloid leukaemia Pharm Research Associates (UK) Limited 26/08/2005
Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) EU/3/04/254 Treatment of myelodysplastic syndromes Accelsiors CRO & Consultancy Services GmbH 21/12/2004
Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) EU/3/04/252 Treatment of chronic myeloid leukemia Accelsiors CRO & Consultancy Services GmbH 21/12/2004
Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) EU/3/04/253 Treatment of acute myeloid leukaemia Accelsiors CRO & Consultancy Services GmbH 21/12/2004
vandetanib EU/3/05/344 Treatment of medullary thyroid carcinoma AstraZeneca UK Limited 24/01/2006
Xaliproden hydrochloride EU/3/00/015 Treatment of amyotrophic lateral sclerosis SANOFI 17/01/2001